165 related articles for article (PubMed ID: 35179724)
1. Managing Headache Disorders Associated with Tuberous Sclerosis and Neurofibromatosis.
Patniyot I; Qubty W
Curr Pain Headache Rep; 2022 Apr; 26(4):281-288. PubMed ID: 35179724
[TBL] [Abstract][Full Text] [Related]
2. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
[TBL] [Abstract][Full Text] [Related]
3. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.
Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J
Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
5. Molecular therapies for tuberous sclerosis and neurofibromatosis.
Franz DN; Weiss BD
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):294-301. PubMed ID: 22544507
[TBL] [Abstract][Full Text] [Related]
6. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
7. Phakomatoses.
Becker B; Strowd RE
Dermatol Clin; 2019 Oct; 37(4):583-606. PubMed ID: 31466597
[TBL] [Abstract][Full Text] [Related]
8. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.
Kokkinou E; Roka K; Alexopoulos A; Tsina E; Nikas I; Krallis P; Thanopoulou I; Nasi L; Makrygianni E; Tsoutsou E; Kosma K; Tsipi M; Tzetis M; Frysira H; Kattamis A; Pons R
Postgrad Med; 2019 Sep; 131(7):445-452. PubMed ID: 31443616
[TBL] [Abstract][Full Text] [Related]
9. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
10. Subependymal giant cell tumors in tuberous sclerosis complex.
Goh S; Butler W; Thiele EA
Neurology; 2004 Oct; 63(8):1457-61. PubMed ID: 15505165
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
12. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T; Niida Y
No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
[TBL] [Abstract][Full Text] [Related]
13. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective.
Berhouma M
World J Pediatr; 2010 May; 6(2):103-10. PubMed ID: 20490765
[TBL] [Abstract][Full Text] [Related]
14. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
[TBL] [Abstract][Full Text] [Related]
15. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
[TBL] [Abstract][Full Text] [Related]
16. Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex.
Tsai JD; Wei CC; Tsao TF; Hsiao YP; Tsai HJ; Yang SH; Tsai ML; Sheu JN
Childs Nerv Syst; 2016 Jan; 32(1):89-95. PubMed ID: 26552385
[TBL] [Abstract][Full Text] [Related]
17. The genetics and diagnosis of pediatric neurocutaneous disorders: Neurofibromatosis and tuberous sclerosis complex.
Tolliver S; Smith ZI; Silverberg N
Clin Dermatol; 2022; 40(4):374-382. PubMed ID: 35248688
[TBL] [Abstract][Full Text] [Related]
18. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
Cappellano AM; Senerchia AA; Adolfo F; Paiva PM; Pinho R; Covic A; Cavalheiro S; Saba N
Childs Nerv Syst; 2013 Dec; 29(12):2301-5. PubMed ID: 23743818
[TBL] [Abstract][Full Text] [Related]
19. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging diagnosis of subependymal giant cell astrocytomas in follow-up of children with tuberous sclerosis complex: should we always use contrast enhancement?
Gaillard AL; Crombé A; Jecko V; Bessou P; Havez M; Pédespan JM; Van Gils J; Chateil JF
Pediatr Radiol; 2020 Sep; 50(10):1397-1408. PubMed ID: 32671416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
